



**Larka**

**Press release**

Merger & Acquisition

4<sup>th</sup> of December, 2018

# Larka provided Archimed with an **Integrated due-diligence** for their investment in **Clean Cells**.



**ArchiMed**

Investors & Entrepreneurs  
in Healthcare

**clean cells**

SOLUTION FOR BIOLOGICS



## **Integrated due-diligence**

Value creating insights come from an integrated, 360-degree view, diligence process that aggregates strategic, commercial, technical and organizational analysis, and gauges how pulling a lever in one specific area of the business will affect all other operations and assumptions within the whole organization.

Larka has developed a unique Integrated Due-Diligence solution for Private Equity firms, built on nearly 30 years of in-depth strategic, commercial, technical and organizational diagnostics performed on hundreds of industry players – *BioPharma companies, CROs, CDMOs, CMOs, analytical testing Labs, and equipment suppliers.*

Our Integrated Due-Diligence solution combines Commercial Due-Diligence, Technical Due-Diligence and Operational Due-Diligence under one roof. It provides PE firms with both, a full appreciation of the capabilities, synergies and risks involved and a full-potential vision for the business, along with the capital, time, resources and organization it will take to run the optimal post-acquisition plan.

## **Contact**

Pierre-Anthony Brioir, Director  
+33 650 630 286  
[pabrioir@larka.fr](mailto:pabrioir@larka.fr)

Adrien Chalmont, Manager  
+33 621 006 115  
[achalmont@larka.fr](mailto:achalmont@larka.fr)

# **Larka is pleased to announce that it performed the Commercial Due-Diligence, Operational Due-Diligence and Technical Due-Diligence for Archimed, the new shareholders of Clean Cells.**

Larka M&A division advised Archimed on all strategic, commercial, operational and technical aspects of the transaction, including quality & regulatory.

Archimed acquired a majority stake in Clean Cells, a leading European player in contract testing – *biosafety testing* – and cell-banking.

Founded in 2000 and based in Boufféré, France, Clean Cells has 60 employees and offers outsourcing services in biosafety testing and cell-banking, with the plan to develop services in process development and contract manufacturing of biopharmaceuticals, including gene therapies and phage therapies.

Larka performed an **Integrated due-diligence** to support Archimed during the acquisition of Clean Cells.

Pierre-Anthony Brioir, Director at Larka, commented: “We are proud to have collaborated as strategic advisors with Clean Cells during this M&A process and very happy they have concluded this deal which attracted many PE and industrial players. Clean Cells’s strategic plan to develop services in biologics process development and manufacturing, combined with their strong expertise in biosafety testing, is very promising. We are convinced that Archimed team, which has a deep knowledge of the industry, will build a European leader in Biosafety testing and biologics contract development and manufacturing.”

## **About Larka**

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit [www.larka.com](http://www.larka.com)

## **About Archimed**

ArchiMed is a healthcare private equity investment firm headquartered in Lyon. The 30-persons team comprising 10 nationalities was founded in 2014 by former 3i Healthcare leaders as the first independent, Pan-European private equity group focused exclusively on the healthcare sector. ArchiMed invests in all healthcare sectors, including Medtech, Biopharma, and Care Services. Over the last 30 years, the ArchiMed partners have directly managed and invested in more than 40 healthcare companies throughout the world, with a combined value above €5bn.

For more information, please visit <https://archimed-group.eu>